These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26848980)

  • 41. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
    Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
    Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer.
    Sun NX; Ye C; Zhao Q; Zhang Q; Xu C; Wang SB; Jin ZJ; Sun SH; Wang F; Li W
    PLoS One; 2014; 9(7):e100340. PubMed ID: 25007342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
    Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
    Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer.
    Sun Y; Ren D; Zhou Y; Shen J; Wu H; Jin X
    Cell Death Dis; 2021 Sep; 12(10):878. PubMed ID: 34564701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased long non-coding RNA lincFOXF1 indicates poor progression and promotes cell migration and metastasis in osteosarcoma.
    Yang S; Chen J; Lv B; Zhang J; Li D; Huang M; Yuan L; Yin G
    J Cell Mol Med; 2020 Nov; 24(21):12633-12641. PubMed ID: 32945076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LINC01116 promotes proliferation, invasion and migration of osteosarcoma cells by silencing p53 and EZH2.
    Zhang ZF; Xu HH; Hu WH; Hu TY; Wang XB
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6813-6823. PubMed ID: 31486480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
    Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
    Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.
    Huo Y; Li Q; Wang X; Jiao X; Zheng J; Li Z; Pan X
    Oncotarget; 2017 Jul; 8(29):46993-47006. PubMed ID: 28388584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LncRNA SNHG17 promotes gastric cancer progression by epigenetically silencing of p15 and p57.
    Zhang G; Xu Y; Wang S; Gong Z; Zou C; Zhang H; Ma G; Zhang W; Jiang P
    J Cell Physiol; 2019 Apr; 234(4):5163-5174. PubMed ID: 30256413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
    Aghdassi A; Sendler M; Guenther A; Mayerle J; Behn CO; Heidecke CD; Friess H; Büchler M; Evert M; Lerch MM; Weiss FU
    Gut; 2012 Mar; 61(3):439-48. PubMed ID: 22147512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2.
    Guo Y; Bai M; Lin L; Huang J; An Y; Liang L; Liu Y; Huang W
    Biomed Pharmacother; 2019 Oct; 118():109272. PubMed ID: 31376657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer.
    Jiao F; Hu H; Yuan C; Wang L; Jiang W; Jin Z; Guo Z; Wang L
    Oncol Rep; 2014 Dec; 32(6):2485-92. PubMed ID: 25269958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of long non-coding RNA PVT1 on cell proliferation and migration in melanoma.
    Chen L; Ma D; Li Y; Li X; Zhao L; Zhang J; Song Y
    Int J Mol Med; 2018 Mar; 41(3):1275-1282. PubMed ID: 29286144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer.
    Yang J; Zhang X; Zhang Y; Zhu D; Zhang L; Li Y; Zhu Y; Li D; Zhou J
    J Exp Clin Cancer Res; 2016 Feb; 35():26. PubMed ID: 26842802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of MALAT-1 in the invasion and metastasis of gastric cancer.
    Chen D; Liu L; Wang K; Yu H; Wang Y; Liu J; Guo Y; Zhang H
    Scand J Gastroenterol; 2017; 52(6-7):790-796. PubMed ID: 28276823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetic silencing of E-cadherin gene induced by lncRNA MALAT-1 in acute myeloid leukaemia.
    Huang J; Fang J; Chen Q; Chen J; Shen J
    J Clin Lab Anal; 2022 Aug; 36(8):e24556. PubMed ID: 35747989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The carcinogenic complex lncRNA DUXAP8/EZH2/LSD1 accelerates the proliferation, migration and invasion of colorectal cancer.
    Gong A; Huang Z; Ge H; Cai Y; Yang C
    J BUON; 2019; 24(5):1830-1836. PubMed ID: 31786844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
    Fujii S; Ochiai A
    Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
    Chen DL; Zhang DS; Lu YX; Chen LZ; Zeng ZL; He MM; Wang FH; Li YH; Zhang HZ; Pelicano H; Zhang W; Xu RH
    Oncotarget; 2015 May; 6(13):10868-79. PubMed ID: 25869101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway.
    Kurihara H; Maruyama R; Ishiguro K; Kanno S; Yamamoto I; Ishigami K; Mitsuhashi K; Igarashi H; Ito M; Tanuma T; Sukawa Y; Okita K; Hasegawa T; Imai K; Yamamoto H; Shinomura Y; Nosho K
    Oncotarget; 2016 Mar; 7(11):12704-17. PubMed ID: 26871294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.